<DOC>
	<DOC>NCT02583022</DOC>
	<brief_summary>The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged â‰¥ 20 years with mild to moderate atopic dermatitis. All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<criteria>Male or female patients aged between 20 and 65 years old Patients with atopic dermatitis, diagnosed according to Hanifin and Rajka diagnostic criteria SCORAD (SCORing Atopic Dermatitis) Score less than 40 Patients presenting symptoms of systemic infection at screening Patients who had been treated with oral steroids, oral antibiotics, systemic phototherapy, or immunosuppressants within the last 1 month prior to the investigational product administration Patients who had been treated with topical steroids or antibiotics within the last 2 weeks prior to the investigational product administration Pregnant women or breastfeeding women Women of childbearing potential or women who are planning a pregnancy during the study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>